Inventor · disambiguated record
Scott E. Strome
Also filed as: STROME SCOTT · STROME SCOTT E
21 granted patents·24 pending applications·702 citations·filing 1998–2024
97Inventor score
Files withUNIV MARYLAND14MAYO FOUNDATION10STROME SCOTT E6MAYO FOUND MEDICAL EDUCATION & RES5CHEN LIEPING4
Top patents by PatentIndex Score
45 records- 0198US7892540B2B7-H1 and methods of diagnosis, prognosis, and treatment of cancerMAYO FOUNDATION·Filed 2005·Granted Feb 22, 2011·84 cites·22 claims
- 0298US7794710B2Methods of enhancing T cell responsivenessMAYO FOUNDATION·Filed 2002·Granted Sep 14, 2010·165 cites·20 claims
- 0397US10941191B2Immunoglobulin constant region Fc receptor binding agentsUNIV MARYLAND·Filed 2018·Granted Mar 9, 2021·8 cites·23 claims
- 0497US8772026B2Enhancement of immune responses by 4-1 BB-binding agentsCHEN LIEPING·Filed 2012·Granted Jul 8, 2014·26 cites·18 claims
- 0596US10851154B2Immunoglobulin constant region Fc receptor binding agentsUNIV MARYLAND·Filed 2016·Granted Dec 1, 2020·8 cites·12 claims
- 0696US9926362B2Immunoglobulin constant region Fc receptor binding agentsUNIV MARYLAND·Filed 2017·Granted Mar 27, 2018·16 cites·25 claims
- 0796US8680237B2Immunoglobulin constant region FC receptor binding agentsSTROME SCOTT E·Filed 2008·Granted Mar 25, 2014·47 cites·15 claims
- 0895US10208105B2Immunoglobulin constant region Fc receptor binding agentsUNIV MARYLAND·Filed 2018·Granted Feb 19, 2019·12 cites·20 claims
- 0995US8747833B2B7-H1 and methods of diagnosis, prognosis, and treatment of cancerCHEN LIEPING·Filed 2011·Granted Jun 10, 2014·23 cites·3 claims
- 1095US7651686B2Enhancement of immune responses by 4-1bb-binding agentsMAYO FOUNDATION·Filed 2002·Granted Jan 26, 2010·46 cites·28 claims
- 1194US9512210B2Immunoglobulin constant region Fc receptor binding agentsUNIV MARYLAND·Filed 2014·Granted Dec 6, 2016·17 cites·12 claims
- 1294US9512208B2Immunoglobulin constant region FC receptor binding agentsUNIV MARYLAND·Filed 2013·Granted Dec 6, 2016·15 cites·2 claims
- 1393US9803015B2Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic targetMAYO FOUNDATION·Filed 2016·Granted Oct 31, 2017·8 cites·7 claims
- 1493US8163550B2Enhancement of immune responses by 4-1BB-binding agentsCHEN LIEPING·Filed 2009·Granted Apr 24, 2012·21 cites·19 claims
- 1593US7449300B2Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cellsMAYO FOUNDATION·Filed 2003·Granted Nov 11, 2008·44 cites·11 claims
- 1691US2024352120A1Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic targetMAYO FOUND MEDICAL EDUCATION & RES·Filed 2024·Application pending·0 cites
- 1788US8263560B2HPV 16 peptide vaccine for head and neck cancerSTROME SCOTT E·Filed 2007·Granted Sep 11, 2012·4 cites·15 claims
- 1881US11939378B2Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic targetMAYO FOUND MEDICAL EDUCATION & RES·Filed 2021·Granted Mar 26, 2024·0 cites·3 claims
- 1980US6591140B2Apparatus and system for stimulating mouth musclesMAYO FOUNDATION·Filed 2000·Granted Jul 8, 2003·34 cites·20 claims
- 2079US11242387B2Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic targetMAYO FOUND MEDICAL EDUCATION & RES·Filed 2019·Granted Feb 8, 2022·0 cites·1 claims
- 2178US2021277091A1Immunoglobulin constant region fc receptor binding agentsUNIV MARYLAND·Filed 2021·Application pending·0 cites
- 2268US2018179281A1Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic targetMAYO FOUND MEDICAL EDUCATION & RES·Filed 2018·Application pending·0 cites
- 2367US2018100015A1Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic targetMAYO FOUND MEDICAL EDUCATION & RES·Filed 2017·Application pending·0 cites
- 2467US2015044165A1Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic targetMAYO FOUNDATION·Filed 2014·Application pending·0 cites
- 2565US2014335075A1Immunoglobulin constant region fc receptor binding agentsGLIKNIK INC·Filed 2013·Application pending·0 cites
- 2663US2016280768A1Immunoglobulin constant region fc receptor binding agentsUNIV MARYLAND·Filed 2016·Application pending·0 cites
- 2763US2016257953A1Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic targetMAYO FOUNDATION·Filed 2016·Application pending·0 cites
- 2861US2012309941A1Immunoglobulin constant region fc receptor binding agentsSTROME SCOTT E·Filed 2012·Application pending·0 cites
- 2961US2016264667A1Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic targetMAYO FOUNDATION·Filed 2015·Application pending·0 cites
- 3061US2011070252A1Mage-a3/hpv 16 peptide vaccines for head and neck cancerMAYO FOUNDATION·Filed 2010·Application pending·0 cites
- 3160US6015419ARetractable surgical scalpelSTROME STEEL SURGICAL INC·Filed 1998·Granted Jan 18, 2000·124 cites·20 claims
- 3260US2006222656A1MAGE-A3/HPV 16 peptide vaccines for head and neck cancerUNIV MARYLAND·Filed 2006·Application pending·0 cites
- 3355US11440946B2Universal antibody-mediated biosensorUNIV MARYLAND·Filed 2016·Granted Sep 13, 2022·0 cites·14 claims
- 3455US2010183646A1Mage-a3/hpv 16 peptide vaccines for head and neck cancerUNIV MARYLAND·Filed 2010·Application pending·0 cites
- 3550US2014370012A1Fusion proteins comprising igg2 hinge domainsGLIKNIK INC·Filed 2013·Application pending·0 cites
- 3650US2012058047A9Method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetectionSTROME SCOTT E·Filed 2010·Application pending·0 cites
- 3749US2023320623A1Breath collector and method for diagnosis and/or monitoringUNIV TENNESSEE RES FOUND·Filed 2021·Application pending·0 cites
- 3849US2010173323A1Glycosylation engineered antibody therapyUNIV MARYLAND·Filed 2007·Application pending·0 cites
- 3948US2012027759A1Methods of enhancing t cell responsivenessCHEN LIEPING·Filed 2010·Application pending·0 cites
- 4047US2008019905A9Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetectionSTROME SCOTT E·Filed 2005·Application pending·0 cites
- 4146US2009130144A1Direct vaccination of the bone marrowUNIV MARYLAND·Filed 2006·Application pending·0 cites
- 4244US2021079402A1Inhibition of zscan4 for inhibition of tumor growthUNIV MARYLAND·Filed 2019·Application pending·0 cites
- 4339US2018282424A1Molecules with bimodal activity depleting target at low dose and increasing immunosuppression at higher doseGLIKNIK INC·Filed 2015·Application pending·0 cites
- 4439US2006182744A1Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereofSTROME SCOTT E·Filed 2005·Application pending·0 cites
- 4536US2012076722A1Methods for treating cancers and diseases associated with 4-1bb (cd137) expressionSTROME SCOTT·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Scott E. Strome files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →